Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Midatech completes cancer side-effect treatment deal

Zuplenz is treatment to prevent nausea and vomiting stemming from radiation-based cancer treatments.
Midatech completes cancer side-effect treatment deal
The treatment is an anti-emetic oral-soluble film

Fast growing drug delivery group Midatech (LON:MTPH, NASDAQ:MTP) has completed the acquisition of Zuplenz, a treatment for the side effects of chemotherapy.

Zuplenz is treatment to prevent nausea and vomiting stemming from radiation-based cancer treatments.

Dr Jim Phillips, chief executive, said: "We are pleased to complete the acquisition of Zuplenz, which adds to our rapidly growing portfolio of marketed oncology products. 

“We believe that our recent product acquisitions will help drive the group towards sustainable profitability."

The treatment is an anti-emetic oral-soluble film which has a target market of US$4.6bn by 2018.

The fact that it does not need to be injected or swallowed is what differentiates it, said Midatech.

It will use the commercial infrastructure that came with recent US acquisition DARA Biosciences to distribute Zuplenz, which also complements its three existing marketed oncology products.

Midatech will pay Zuplenz’s current owner, Galena Biopharma (NASDAQ:GALE), US$3.75mln upfront, but this total could rise eventually by a further US$26mln depending on its success.

Jonny.jpg
Why Invest In Midatech Pharma Plc? Read More Here

Register here to be notified of future MTPH Company articles
View full MTPH profile

Midatech Pharma Plc Timeline

Big Picture
November 22 2016

Related Articles

picture of drug lab
February 07 2017
Amryt Pharma’s strategy to acquire, in-license and then develop drugs for hard to treat, so-called orphan diseases has been seeing some good progress.
GW_Pharma.png
November 22 2016
With the balance sheet now significantly strengthened, we anticipate the company is well-positioned to capture value in areas where its technology platforms offer material improvements for patient care - Panmure Gordon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.